Jonathan Edwards
Senior Member (Voting Rights)
I see that West is a UCL psychologist who works on tobacco addiction. Presumably Cochrane have shown his treatment 'works'.
This group produces reviews on the effectiveness of interventions to reduce smoking. I believe they are one of the more "successful" UK groups - in that they gain kudos for Cochrane. They probably already work pretty closely with NICE, but I don't know that for sure.We all rely on the Cochrane Tobacco Addiction Group's work.
This has to be dog-whistling to someone. Why should anyone need a Tobacco Addiction Group?
Tobacco should obviously not be sold for profit. The problem is simply a political one.
I think the point is NICE will move the current policy of always using their own assessors (expensive), to commissioning Cochrane for some of the work (presumably cheaper as Cochrane doesn't pay its reviewers). They will pay Cochrane something, obviously, but it won't be as expensive as having their own trained, paid (but guaranteed impartial) assessors looking at everythingHere's an extract from a response I received from NICE*. Assuming these statements, from NICE, are accurate (I copied my responses to the ME/CFS APPG & Covid APPG - so they had better be!) then NICE independently assesses the evidence. If so then where is the saving?
*NICE to me:
"Each review question in the NICE guideline has its own review protocol agreed by the guideline committee. These protocols are different to those used by Cochrane reviews (for example, different inclusion and exclusion criteria), and the NICE guideline conducted its own independent systematic reviews based on Developing NICE guidelines: the manual<https://www.nice.org.uk/process/pmg20/chapter/introduction>.
In terms of quality assessment of the evidence, the NICE guideline committee exercised their clinical judgement to decide which components of GRADE were important for downgrading evidence quality, for example, risk of bias, population directness, and threshold(s) for minimal clinically important differences. The full details of the review protocol and data analysis relating to exercise therapy in NG206 can be found in Evidence review [G] for the non-pharmacological management of ME/CFS<https://www.nice.org.uk/guidance/ng...acological-management-of-mecfs-pdf-9265183028>. The clinical evidence summary tables for exercise interventions, including GRADE analysis, begin on p.147.
These differences between the methods and processes of Cochrane reviews and NICE guidelines can result in different quality ratings of the evidence in GRADE, as in this case with exercise therapy for ME/CFS."
Yea I think there were some weasel words in NICEs reply i.e. assurances that NICE would review the evidence independently (of Cochrane) in accordance with the NICE guideline.I think the point is NICE will move the current policy of always using their own assessors (expensive), to commissioning Cochrane for some of the work (presumably cheaper as Cochrane doesn't pay its reviewers). They will pay Cochrane something, obviously, but it won't be as expensive as having their own trained, paid (but guaranteed impartial) assessors looking at everything
So hold on a mo. If reviewers genuinely get nothing out of doing Cochrane reviews then that is exploitation plain and simple. There must be a benefit of some kind, for these reviewers to put in the huge hours that a thorough review would entail.
So if unpaid reviewers have another ulterior motive (which in my view they must) then that motive (explicitly stated or not) should immediately make them unsuitable as reviewers.
If Cochrane want to collate reviews written by volunteers with their own motivations, then that is up to them, but surely NICE are getting into very murky territory if they effectively support a zero-pay model?
Either NICE are supporting exploitation, or they acknowledge that the reviewers are gaining some other benefit from doing these reviews. If Cochrane reviewers are gaining in another undisclosed way, then NICE must surely recognise that Cochrane reviewers cannot be guaranteed to be impartial?
Edit to add: Have I over simplified the situation? What am I missing here?
I think the problem with Cochrane is that who gets to do any of this is all a bit arbitrary - and indeed dependent on ulterior motives.
The issue of payment is complicated. If systematic reviews are a good way to make sure clinical practice is evidence based then they can be seen as a legitimate part of the work of clinical academic staff. Doing reviews, like doing research or writing papers is seen as part of the way academics justify their existence - and reasonably so - part of the learning process.
As far as I understand it, the same (paid) NICE technical staff with no conflicts do the trawling, categorisation, and the evaluation of evidence quality. The (unpaid) committee are supposed to be as free of conflict as possible, and have no connection with the technical team who present the evidence (unlike in Cochrane reviews where they are all one big happy family). The committee are presented with the evidence already quality (GRADE) evaluated. In the ME/CFS guideline, the committee also took into account the bias caused by relying on subjective outcomes in unblindable trials - not taken into account by GRADE - but I think that is unusual (unprecedented??)One is the data trawling and categorisation - which at NICE is done by technical staff with no conflicts of interest. The other is evaluation - which at NICE is done by people on a committee who are unpaid and who may have conflicts of interest just like at Cochrane.
I guess we'll know more if we get sight of the Agreement. From the September 1st media release and the NICE strategy statement:In their response to me NICE stated that the evaluate all reviews i.e. they do not use Cochrane reviews without reviewing them. If true then what use is the link to Cochrane i.e. if NICE has to carry out their own evaluation?
EDIT - I've posted an extract from NICEs email to me below.
Yes as a "management approach", and assuming that management neither know nor care (to be fair I've experienced that), then it makes "sense"! Bear in mind @strategist comments that with suitably subjective outcome criteria even homeopathy can be shown to work and GRADE/Cochrane looks like vehicle to prove it ---- unblinded studies with subjective outcome criteria are considered moderate quality evidence!
As per @Caroline Struthers ---------
The committee are presented with the evidence already quality (GRADE) evaluated.
It clearly incentivizes people who can get BS through this way that can't pass scrutiny under a normal context. It seems to be the main appeal, frankly. Can't get a bad idea that doesn't work through peer review? Just get involved into arbitrating for yourself.So hold on a mo. If reviewers genuinely get nothing out of doing Cochrane reviews then that is exploitation plain and simple. There must be a benefit of some kind, for these reviewers to put in the huge hours that a thorough review would entail.
So if unpaid reviewers have another ulterior motive (which in my view they must) then that motive (explicitly stated or not) should immediately make them unsuitable as reviewers.
Basically people get involved because using Cochrane this way gives them an advantage
That grates given the amount of time and effort @Caroline Struthers has spent trying to get Cochrane to remove redundant reviews.The key phrase seems to be "dynamic, living guideline recommendations" so presumably the value of the agreement with Cochrane is whether it measurably contributes to fulfilling that part of the NICE five year strategy.
Normally I'd consider such a multiplicy of organisations to preclude any viable attempt at stacking the odds but as there are no obvious Chinese Walls between NHSE, NHSI and NIHR I'm not so confident.
ah. ok. I didn't know that.I don't think it is quite as simple as that. The technical team take note of the views of the committee and evidence presented to the committee in coming to a final evaluation.
Exactly! You don't get money for doing reviews, you get membership of Cochrane and publication in a "high impact" journal (The Cochrane Library) which will never retract your review however bad or misleading it is - fantastic! If Cochrane team up with NICE, they can sell this to their authors as an added extra incentive. If NICE use your review, it is now truly untouchable as a piece of great scienceon that point it is interesting to see the comment:
Dr Karla Soares-Weiser, Editor in Chief of the Cochrane Library, said: “This agreement has collaborative benefits for all involved. NICE will get the findings of Cochrane Reviews to use in their deliberations, Cochrane groups will be able to respond by producing high priority reviews, and for Cochrane review authors, it guarantees impact.
NICE and Cochrane sign collaborative agreement to deliver ‘living’ guideline recommendations | News and features | News | NICE
I don't think they will ever admit that they are being used and abused - either by BPS enthusiasts nor by academic clinicians with vested interests in particular drugs or devices.but this is how the BPS ideologues are abusing it, and Cochrane appears fine with it.
ah. ok. I didn't know that.
I have a friend who used to work for NICE and then worked for Cochrane as a contracted systematic reviewer on a suite of Cochrane reviews. She left Cochrane absolutely appalled by the vested interests, the waste, and she was bullied by her boss and the lead statistician on the project to use methods she wasn't comfortable with. She told a story of a Cochrane lead author insisting on including a randomized trial with seven participants. She had many many stories.I don't think it is quite as simple as that. The technical team take note of the views of the committee and evidence presented to the committee in coming to a final evaluation.
I have a friend who used to work for NICE and then worked for Cochrane as a contracted systematic reviewer on a suite of Cochrane reviews. She left Cochrane absolutely appalled by the vested interests, the waste, and she was bullied by her boss and the lead statistician on the project to use methods she wasn't comfortable with. She told a story of a Cochrane lead author insisting on including a randomized trial with seven participants. She had many many stories.
I can check this, but I thought she told me that NICE technical review teams did not take views of the committee into account when presenting the evidence. They would work to the protocol set out by the committee, but that's not the same thing surely. I *think* she also said that at NICE they used GRADE much more strictly than at Cochrane. So if a study is downgraded in one of the five domains - risk of bias, inconsistency, indirectness, imprecision and publication bias - then it could not be graded higher in another domain. Makes sense.
[edited for clarity]
I can check this, but I thought she told me that NICE technical review teams did not take views of the committee into account when presenting the evidence. They would work to the protocol set out by the committee, but that's not the same thing surely.